(Reuters) - Endo's lead product Lidoderm, a pain patch, accounted for
more than 60 percent of the company's net sales in 2006.
The investor group also raised concerns about the company's
capital structure and cash position. It stated that Endo's
decision to hold cash in its balance sheet while evaluating
options was affecting the company's value.
Read more at Reuters.com Government Filings News
more than 60 percent of the company's net sales in 2006.
The investor group also raised concerns about the company's
capital structure and cash position. It stated that Endo's
decision to hold cash in its balance sheet while evaluating
options was affecting the company's value.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment